R

REGENXBIO

D
RGNX
USD
1.87
(20.0644%)
Market Closed
38,736.00
Volume
-4.83
EPS
-
Div Yield
-2.137405
P/E
553,045,473.72
Market Cap
Today
18.7898%
1 Week
30.268%
1 Month
17.542%
6 Months
-34.060%
12 Months
-31.934%
Year To Date
-37.625%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CRSP
1.04
(2.0444%)
USD
N
NTLA
0.31
(1.9745%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
S
SGMO
0.33
(13.3603%)
USD
VRTX
VRTX
9.22
(1.869%)
USD
B
BLUE
-0.0729
(-16.2614%)
USD
ALNY
ALNY
-0.795
(-0.2913%)
USD
R
RARE
-0.1
(-0.1979%)
USD
S
SRPT
-7.62
(-5.9531%)
USD
Q
QURE
0.26
(3.6212%)
USD

Title:
REGENXBIO

Sector:
Healthcare
Industry:
Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Do you need help or have a question?
Contact Us